Radiopharm Theranostics Limited (RADX)
NASDAQ: RADX · Real-Time Price · USD
1.110
-0.040 (-3.48%)
At close: Oct 8, 2026, 4:00 PM EDT
1.000
-0.110 (-9.91%)
Pre-market: Oct 9, 2026, 5:17 AM EDT
Radiopharm Theranostics Revenue
In the fiscal year ending June 30, 2026, Radiopharm Theranostics had annual revenue of 12.87M AUD, down -1.05%. Radiopharm Theranostics had revenue of 6.66M in the half year ending June 30, 2026.
Revenue (ttm)
12.87M AUD
Revenue Growth
-1.05%
P/S Ratio
1.69
Revenue / Employee
918,938 AUD
Employees
14
Market Cap
15.08M USD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | 12.87M | -136.84K | -1.05% |
| Jun 30, 2025 | 13.00M | 11.41M | 716.81% |
| Jun 30, 2024 | 1.59M | -4.62M | -74.37% |
| Jun 30, 2023 | 6.21M | - | - |
| Jun 30, 2022 | - | - | - |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Palatin Technologies | 13.19M |
| Dyadic International | 3.80M |
| Marker Therapeutics | 3.55M |
| Lipocine | 1.57M |
| Allarity Therapeutics | 345.00K |
| Kiora Pharmaceuticals | 20.00K |
| BioCardia | 3.00K |
RADX News
- 3 days ago - Radiopharm completes EOP2 meeting with FDA for RAD101 - TheFly
- 9 days ago - Radiopharm Theranostics Annual report: H2 2026 - Filings
- 24 days ago - Radiopharm Theranostics Registration statement: Registration filing - Filings
- 4 weeks ago - Radiopharm announces data from imaging trial of RAD 301 - TheFly
- 4 weeks ago - Radiopharm Theranostics Announces Positive Data from the Phase 1 Imaging Trial of RAD301 in Patients with Pancreatic Ductal Adenocarcinoma - GlobeNewsWire
- 6 weeks ago - Radiopharm doses first patient in second cohort of RV-01 trial - TheFly
- 6 weeks ago - Radiopharm Theranostics Doses First Patient in Second Cohort of Phase 1/2a Clinical Trial of BetaBart (RV-01) in B7-H3 Expressing Solid Tumors - GlobeNewsWire
- 7 weeks ago - Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee to Advance to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Clinical Trial - GlobeNewsWire